BNP Paribas Asset Management
IOVA icon

BNP Paribas Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

BNP Paribas Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3K Buy
4,875
+577
+13% +$2.19K ﹤0.01% 2046
2026
Q1 		$15.1K Buy
4,298
+1,102
+34% +$3.52K ﹤0.01% 2102
2025
Q4 		$9K Buy
3,196
+976
+44% +$2.26K ﹤0.01% 2172
2025
Q3 		$5K Buy
+2,220
New +$5.24K ﹤0.01% 1828

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

BNP Paribas Asset Management's IOVA Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Iovance Biotherapeutics (IOVA) stake by 13% in Q2 2026, buying an estimated $2.19K and bringing the position to 4,875 shares worth $20.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2046.

BNP Paribas Asset Management first reported a position in IOVA in Q3 2025 and has held it in 4 quarters since. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • BNP Paribas Asset Management held 4,875 shares of Iovance Biotherapeutics worth $20.3K as of Q2 2026.
  • BNP Paribas Asset Management bought 577 Iovance Biotherapeutics shares in Q2 2026, an estimated $2.19K.
  • Iovance Biotherapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #2046 holding.
  • BNP Paribas Asset Management first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.